{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:43:47Z","timestamp":1788349427804,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Integrative Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.joim.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:39:21Z","timestamp":1723167561000},"page":"614-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series"],"prefix":"10.1016","volume":"22","author":[{"given":"Yong-guang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.joim.2024.08.001_b0005","first-page":"2712","article-title":"Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia","volume":"92","author":"De Botton","year":"1998","journal-title":"Eur APL Group Blood"},{"issue":"15","key":"10.1016\/j.joim.2024.08.001_b0010","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.joim.2024.08.001_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.17221","article-title":"Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens","volume":"192","author":"Fouzia","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.joim.2024.08.001_b0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers11101591","article-title":"Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies","volume":"11","author":"Noguera","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"33","key":"10.1016\/j.joim.2024.08.001_b0025","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2013.48.8312","article-title":"Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial","volume":"31","author":"Zhu","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.joim.2024.08.001_b0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.joim.2024.08.001_b0035","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00277-015-2477-x","article-title":"Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients","volume":"94","author":"Lou","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.joim.2024.08.001_b0040","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.31327","article-title":"Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study","volume":"124","author":"Gill","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.joim.2024.08.001_b0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.13607","article-title":"Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide","volume":"171","author":"Sanford","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.joim.2024.08.001_b0050","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cam4.2883","article-title":"A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide","volume":"9","author":"Kulkarni","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.joim.2024.08.001_b0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clml.2024.01.015","article-title":"Outcome of patients with relapsed acute promyelocytic leukemia","volume":"24","author":"Sasaki","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.joim.2024.08.001_b0060","first-page":"1","article-title":"Efficacy of arsenic trioxide combined with ATRA and chemotherapy for relapsed acute promyelocytic leukemia patients","volume":"28","author":"Li","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.joim.2024.08.001_b0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5045\/br.2022.2022060","article-title":"Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?","volume":"57","author":"Min","year":"2022","journal-title":"Blood Res"},{"issue":"12","key":"10.1016\/j.joim.2024.08.001_b0070","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s00277-022-04954-0","article-title":"Treatment for relapsed acute promyelocytic leukemia","volume":"101","author":"Yanada","year":"2022","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.joim.2024.08.001_b0075","doi-asserted-by":"crossref","first-page":"e14009","DOI":"10.1111\/ctr.14009","article-title":"Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia","volume":"34","author":"Hashmi","year":"2020","journal-title":"Clin Transplant"},{"issue":"12","key":"10.1016\/j.joim.2024.08.001_b0080","doi-asserted-by":"crossref","first-page":"847.e1","DOI":"10.1016\/j.jtct.2022.09.021","article-title":"Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia","volume":"28","author":"Yanada","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.joim.2024.08.001_b0085","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41409-020-01162-0","article-title":"Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission","volume":"56","author":"Sanz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.joim.2024.08.001_b0090","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00277-018-3400-z","article-title":"Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy","volume":"97","author":"Cicconi","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.joim.2024.08.001_b0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/leu.2015.12","article-title":"Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet","volume":"29","author":"Lengfelder","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.joim.2024.08.001_b0100","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1073\/pnas.0712365105","article-title":"Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia","volume":"105","author":"Wang","year":"2008","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496424003716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496424003716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:02:21Z","timestamp":1727452941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095496424003716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2095496424003716"],"URL":"https:\/\/doi.org\/10.1016\/j.joim.2024.08.001","relation":{},"ISSN":["2095-4964"],"issn-type":[{"value":"2095-4964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Integrative Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joim.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}